These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1042 related items for PubMed ID: 20399877

  • 1. Prospective, comprehensive, and effective viral monitoring in children undergoing allogeneic hematopoietic stem cell transplantation.
    Schönberger S, Meisel R, Adams O, Pufal Y, Laws HJ, Enczmann J, Dilloo D.
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1428-35. PubMed ID: 20399877
    [Abstract] [Full Text] [Related]

  • 2. Human herpes virus 6 plasma DNA positivity after hematopoietic stem cell transplantation in children: an important risk factor for clinical outcome.
    de Pagter PJ, Schuurman R, Visscher H, de Vos M, Bierings M, van Loon AM, Uiterwaal CS, van Baarle D, Sanders EA, Boelens J.
    Biol Blood Marrow Transplant; 2008 Jul; 14(7):831-9. PubMed ID: 18541204
    [Abstract] [Full Text] [Related]

  • 3. Observational prospective study of viral infections in children undergoing allogeneic hematopoietic cell transplantation: a 3-year GETMON experience.
    Verdeguer A, de Heredia CD, González M, Martínez AM, Fernández-Navarro JM, Pérez-Hurtado JM, Badell I, Gómez P, González ME, Muñoz A, Díaz MA, GETMON: Spanish Working Party for Blood and Marrow Transplantation in Children.
    Bone Marrow Transplant; 2011 Jan; 46(1):119-24. PubMed ID: 20228849
    [Abstract] [Full Text] [Related]

  • 4. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease.
    Bordon V, Bravo S, Van Renterghem L, de Moerloose B, Benoit Y, Laureys G, Dhooge C.
    Transpl Infect Dis; 2008 Feb; 10(1):19-23. PubMed ID: 17511814
    [Abstract] [Full Text] [Related]

  • 5. [Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients].
    Torre-Cisneros J, Caston-Osorio JJ, Martín C, Rivero A, Doblas A, Rojas R, Gómez P, Martínez F, Torres A.
    Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):6-12. PubMed ID: 19409666
    [Abstract] [Full Text] [Related]

  • 6. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
    Chen XH, Zhang C, Zhang X, Gao L, Gao L, Kong PY, Peng XG, Qi DG, Sun AH, Zeng DF, Liu H, Gong Y, Wang QY.
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
    [Abstract] [Full Text] [Related]

  • 7. [Application of real time polymerase chain reaction to the diagnosis and treatment of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation].
    Chen H, Liu KY, Xu LP, Liu DH, Chen YH, Zhao XS, Yu L, Han W, Zhang XH, Wang Y, Chen Y, Huang XJ.
    Zhonghua Xue Ye Xue Za Zhi; 2009 Feb; 30(2):77-81. PubMed ID: 19563015
    [Abstract] [Full Text] [Related]

  • 8. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B, Pati N, Gilroy N, Ratnamohan M, Huang G, Kerridge I, Hertzberg M, Gottlieb D, Bradstock K.
    Transpl Infect Dis; 2010 Aug 01; 12(4):322-9. PubMed ID: 20487414
    [Abstract] [Full Text] [Related]

  • 9. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
    Burns LJ, Miller W, Kandaswamy C, DeFor TE, MacMillan ML, Van Burik JA, Weisdorf DJ.
    Bone Marrow Transplant; 2002 Dec 01; 30(12):945-51. PubMed ID: 12476289
    [Abstract] [Full Text] [Related]

  • 10. Cytomegalovirus antigenemia and outcomes of patients undergoing allogeneic peripheral blood stem cell transplantation: effects of long-term high-dose acyclovir prophylaxis and preemptive ganciclovir treatment.
    Hazar V, Ugur A, Colak D, Saba R, Tezcan G, Kupesiz A, Karadogan I, Gultekin M, Yesilipek A, Undar L.
    Jpn J Infect Dis; 2006 Aug 01; 59(4):216-21. PubMed ID: 16936338
    [Abstract] [Full Text] [Related]

  • 11. Quantification of adenovirus DNA in unrelated donor hematopoietic stem cell transplant recipients.
    Gustafson I, Lindblom A, Yun Z, Omar H, Engstrom L, Lewensohn-Fuchs I, Ljungman P, Broliden K.
    J Clin Virol; 2008 Sep 01; 43(1):79-85. PubMed ID: 18550426
    [Abstract] [Full Text] [Related]

  • 12. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation.
    Coppoletta S, Tedone E, Galano B, Soracco M, Raiola AM, Lamparelli T, Gualandi F, Bregante S, Ibatici A, di Grazia C, Dominietto A, Varaldo R, Bruno B, Frassoni F, Van Lint MT, Bacigalupo A.
    Biol Blood Marrow Transplant; 2011 Jun 01; 17(6):901-7. PubMed ID: 20950702
    [Abstract] [Full Text] [Related]

  • 13. Cytomegalovirus, adenovirus, and polyomavirus co-infection among pediatric recipients of allogeneic stem cell transplantation: characteristics and outcome.
    Watcharananan SP, Kiertiburanakul S, Piyatuctsanawong W, Anurathapan U, Sungkanuparph S, Pakakasama S, Chantratita W, Hongeng S.
    Pediatr Transplant; 2010 Aug 01; 14(5):675-81. PubMed ID: 20412509
    [Abstract] [Full Text] [Related]

  • 14. Opportunistic virus DNA levels after pediatric stem cell transplantation: serostatus matching, anti-thymocyte globulin, and total body irradiation are additive risk factors.
    Kullberg-Lindh C, Mellgren K, Friman V, Fasth A, Ascher H, Nilsson S, Lindh M.
    Transpl Infect Dis; 2011 Apr 01; 13(2):122-30. PubMed ID: 21457420
    [Abstract] [Full Text] [Related]

  • 15. [Monitoring of early Epstein-Barr virus reactivation and preemptive therapy after allogeneic hematopoietic stem cell transplantation].
    Lu Y, Wu T, Cao XY, Wang JB, Sun Y, Zhao YL, DA WM, Ji SQ, Tong CR, Lu DP.
    Zhonghua Nei Ke Za Zhi; 2011 May 01; 50(5):383-7. PubMed ID: 21624219
    [Abstract] [Full Text] [Related]

  • 16. Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir.
    Verma A, Devine S, Morrow M, Chen YH, Mihalov M, Peace D, Stock W, Pursell K, Wickrema A, Yassine M, Jessop E, van Besien K.
    Bone Marrow Transplant; 2003 May 01; 31(9):813-6. PubMed ID: 12732890
    [Abstract] [Full Text] [Related]

  • 17. Once daily ganciclovir as initial pre-emptive therapy delayed until threshold CMV load > or =10000 copies/ml: a safe and effective strategy for allogeneic stem cell transplant patients.
    Verkruyse LA, Storch GA, Devine SM, Dipersio JF, Vij R.
    Bone Marrow Transplant; 2006 Jan 01; 37(1):51-6. PubMed ID: 16284613
    [Abstract] [Full Text] [Related]

  • 18. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
    Omar H, Hägglund H, Gustafsson-Jernberg A, LeBlanc K, Mattsson J, Remberger M, Ringdén O, Sparrelid E, Sundin M, Winiarski J, Yun Z, Ljungman P.
    Transpl Infect Dis; 2009 Oct 01; 11(5):393-9. PubMed ID: 19497070
    [Abstract] [Full Text] [Related]

  • 19. Prevalence of viral infections and hemorrhagic cystitis in hematopoietic stem cell transplant recipients.
    Shakiba E, Yaghobi R, Ramzi M.
    Exp Clin Transplant; 2011 Dec 01; 9(6):405-12. PubMed ID: 22142049
    [Abstract] [Full Text] [Related]

  • 20. CMV monitoring after peripheral blood stem cell and bone marrow transplantation by pp65 antigen and quantitative PCR.
    Schulenburg A, Watkins-Riedel T, Greinix HT, Rabitsch W, Loidolt H, Keil F, Mitterbauer M, Kalhs P.
    Bone Marrow Transplant; 2001 Oct 01; 28(8):765-8. PubMed ID: 11781628
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.